Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial
Pingali SR, Denai M, Stasi AD, et al.
Key Points:
T-cell replete haploidentical stem cell transplantation (HaploSCT)with non-myeloablative conditioning associated with very low rates of non-relapse mortality (NRM) but high relapse rates
Using a myeloablative conditioning regimen, this stem transplantation approach explored in patients with advanced hematological malignancies
Good disease control rates with acceptable incidence of NRM observed with melphalan-based conditioning regimen after median follow-up of 14 months
Relapse rates particularly lower in Lymphoma/CLL patients
Implications:
- T-cell replete HaploSCT with melphalan-based myeloablative conditioning may represent an effective alternative treatment option for patients with advanced hematologic malignancies
View the original abstract on the ASH website.
